Sarkar Koustav, Bose Anamika, Chakraborty Krishnendu, Haque Enamul, Ghosh Diptendu, Goswami Shyamal, Chakraborty Tathagata, Laskar Subrata, Baral Rathindranath
Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Kolkata 700026, West Bengal, India.
Vaccine. 2008 Aug 12;26(34):4352-62. doi: 10.1016/j.vaccine.2008.06.048. Epub 2008 Jun 30.
In an objective to generate effective carcinoembryonic antigen (CEA) specific anti-tumor immune response in Swiss mice, CEA was presented using macrophages with adjuvant help from neem leaf glycoprotein (NLGP). Such vaccination generates significantly higher antibody (IgG2a) and T cell response than immunization protocol without NLGP. NLGP controls the function of both B cells and macrophages by altering the expressions of various regulatory molecules, like, CD19, CD11b, etc. NLGP also directs CEA vaccination towards Th1 bias, by modulating cytokine secretion. This NLGP-generated anti-CEA immune response would be effective as a vaccine to lyse CEA(+) tumors in vitro and in vivo.
为了在瑞士小鼠中产生有效的癌胚抗原（CEA）特异性抗肿瘤免疫反应，利用巨噬细胞在印楝叶糖蛋白（NLGP）的辅助作用下呈递CEA。与没有NLGP的免疫方案相比，这种疫苗接种产生的抗体（IgG2a）和T细胞反应明显更高。NLGP通过改变各种调节分子如CD19、CD11b等的表达来控制B细胞和巨噬细胞的功能。NLGP还通过调节细胞因子分泌将CEA疫苗接种导向Th1偏向。这种由NLGP产生的抗CEA免疫反应作为一种疫苗在体外和体内裂解CEA(+)肿瘤将是有效的。
